Inhibitors as a therapeutic frontier in lung cancer: Mechanism, opportunities, and molecular docking studies
- 4 August 2025
- journal article
- review article
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt B) , 110889
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Emerging trends of mesoporous silica nanoparticles in colon targeting2025
- RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and FutureDrugs, 2024
- Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug deliveryJournal of Nanoparticle Research, 2023
- Targeted therapies for RET-fusion cancer: Dilemmas and breakthroughBiomedicine & Pharmacotherapy, 2020
- Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistancePharmacological Reports, 2020
- Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung CancerJAMA Network Open, 2019
- Targeting EGFR in Lung Cancer: Current Standards and DevelopmentsDrugs, 2018
- Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2014
- Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases2011
- Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapyMedicinal Research Reviews, 2007